英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
320334查看　320334　在百度字典中的解释百度英翻中〔查看〕
320334查看　320334　在Google字典中的解释Google英翻中〔查看〕
320334查看　320334　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • News - AnaptysBio, Inc.
    Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB) today announced that its planned spin-off, First March 27, 2026
  • AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD . . .
    Faga said AnaptysBio entered the year with $310 million in cash He suggested the royalty business would require limited cash, stating that about $20 million would provide sufficient runway
  • AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD . . .
    AnaptysBio began the year with about $310 million cash; management says the royalty business needs roughly $20 million runway, while the biopharma side would require ~ $100 million to fund ANB033 through phase 2 into late 2027 or ~ $200 million to extend into late 2028, with ANB033 readouts expected by Q4 and rosnilimab showing encouraging
  • Anaptysbio Inc (ANAB) 8-K Earnings Release, Regulated Disclosure - Mar 2026
    SAN DIEGO, March 3, 2026 — AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec 31, 2025
  • FinancialContent - Anaptys Provides Update on Business Separation and . . .
    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec 31, 2025
  • Investor Relations | AnaptysBio, Inc.
    Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company
  • AnaptysBio posts Q4 profit, plans 2026 spin-off | ANAB SEC Filing . . .
    AnaptysBio swings to Q4 2025 profit on $108 2M collaboration revenue, plans Q2 2026 spin-off of First Tracks Biotherapeutics while retaining growing Jemperli and imsidolimab royalty assets
  • How AnaptysBio’s 2026 spin-off plan could reshape its pipeline, royalty
    On the balance sheet, AnaptysBio ended the first quarter of 2025 with $383 million in cash and equivalents, which management says provides runway through 2027 This cash position supports the decision to create two entities—each able to access capital markets on its own terms
  • Anaptys Provides Update on Business Separation and Announces Fourth . . .
    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec 31, 2025
  • Presentations Events - AnaptysBio, Inc.
    The Investor Relations website contains information about AnaptysBio, Inc 's business for stockholders, potential investors, and financial analysts
  • AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge . . .
    Key Points First Tracks Biotherapeutics will be spun out within months, leaving AnaptysBio as a lean, royalty-focused company (fewer than 10 staff, mid‑high 90% EBIT margin) that expects to be GAAP positive and could use leftover cash for returns including buybacks Jemperli currently drives roughly $100 million in annual royalties on a $1 4 billion run rate and, with mid‑teens quarter





中文字典-英文字典  2005-2009